ClinicalTrials.gg
RecruitingNCT07797959Updated Sep 1, 2026

Thread-Embedding Acupuncture as an Adjunct to Proton Pump Inhibitor Therapy for Gastroesophageal Reflux Disease

An interventional study of Thread-Embedding Acupuncture in GERD and Gastroesophageal Reflux Disease, sponsored by University of Science Ho Chi Minh City. Recruiting at 1 site in Vietnam. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by University of Science Ho Chi Minh City · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Apr 2026, registered Aug 2026).
  • Started Apr 2026; still recruiting 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study aims to evaluate the effectiveness of thread-embedding acupuncture combined with omeprazole in patients with gastroesophageal reflux disease (GERD) presenting with the traditional medicine pattern of Liver-Stomach constraint-heat. Participants will receive either thread-embedding acupuncture combined with omeprazole or the comparator treatment according to the study protocol. Clinical outcomes will be assessed to determine the effectiveness and safety of the intervention.

02

Conditions studied

  • GERD
  • Gastroesophageal Reflux Disease

Keywords

  • Liver-Stomach constraint-heat
  • Traditional medicine
  • Acupoint catgut embedding
  • Thread-embedding acupuncture
  • Omeprazole
03

In context

Gastroesophageal Reflux

1,211 studies on the registry are indexed under Gastroesophageal Reflux; 202 are open to participants now.

This study's planned enrollment of 50 is below the median of 68 across 796 interventional studies indexed under Gastroesophageal Reflux.

Browse Gastroesophageal Reflux studies →

Lead sponsor

University of Science Ho Chi Minh City is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 60 years.
  • Diagnosed with gastroesophageal reflux disease (GERD) with a GerdQ score ≥8 and typical heartburn and/or regurgitation occurring at least 2 days per week, and considered eligible for proton pump inhibitor therapy according to the ACG 2013 guideline.
  • Meets the diagnostic criteria for Liver-Stomach Heat Stagnation Syndrome according to the 2017 expert consensus on traditional medicine syndrome differentiation for GERD.
  • No previous diagnosis of GERD within the past 8 weeks.
  • Voluntarily agrees to participate in the study and provides written .

Exclusion criteria

Exclusion Criteria:

  • Presence of alarm symptoms, including dysphagia, odynophagia, palpable lymph nodes or mass, unintentional weight loss, family history of gastrointestinal , gastrointestinal bleeding, anemia, or persistent nausea/vomiting.
  • Structural gastrointestinal disease confirmed by endoscopy, including esophageal malignancy or other significant organic lesions.
  • Current use of medications that may influence GERD assessment or treatment, including , NSAIDs, bisphosphonates, prostaglandins, oral , antifungal agents, or sedative medications.
  • Use of proton pump inhibitors, H2-receptor antagonists, or prokinetic agents within the previous 14 days.
  • History of to proton pump inhibitors or absorbable catgut/thread material.
  • Skin inflammation, infection, or other dermatologic disease at or around the intended thread-embedding sites.
  • Current pregnancy or breastfeeding.
  • Currently participating in another interventional clinical study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Omeprazole

    Participants receive omeprazole according to the treatment regimen specified in the study protocol.

    Procedure: Thread-Embedding Acupuncture

  • Experimental
    Thread-Embedding Acupuncture Plus Omeprazole

    Participants receive thread-embedding acupuncture in combination with omeprazole according to the treatment regimen specified in the study protocol.

    Procedure: Thread-Embedding Acupuncture

Interventions

  • ProcedureThread-Embedding Acupuncture

    Participants will receive acupoint catgut embedding in addition to standard treatment with omeprazole. Acupoint catgut embedding will be performed twice during the 4-week treatment period, at 2-week intervals. Sterile chromic catgut 3/0 will be embedded at Zhongwan (CV12), Shangwan (CV13), Xiawan (CV10), Zusanli (ST36), Tianshu (ST25), and Taichong (LR3) according to the standardized procedure. Participants will be monitored for 30 minutes after each procedure for adverse events.

    Also known as: Acupoint Catgut Embedding

06

What researchers measure

Primary outcomes

  1. Change in GERD-Q Score

    Gastroesophageal reflux disease symptoms will be assessed using the Gastroesophageal Reflux Disease Questionnaire (GerdQ). The total GerdQ score ranges from 0 to 18, with higher scores indicating more severe gastroesophageal reflux disease symptoms. Change in the total GerdQ score from baseline to 4 weeks will be assessed between the two study groups.

    Time frame: Baseline and 4 weeks

Secondary outcomes

  1. Treatment Response Based on GerdQ

    Treatment response will be defined as a reduction of at least 2 points in the total Gastroesophageal Reflux Disease Questionnaire (GerdQ) score from baseline. The total GerdQ score ranges from 0 to 18, with higher scores indicating more severe gastroesophageal reflux disease symptoms. The proportion of participants achieving treatment response will be compared between the two study groups.

    Time frame: Baseline and weekly through 4 weeks

  2. Complete Symptom Resolution Based on GerdQ

    Complete resolution of typical gastroesophageal reflux disease (GERD) symptoms will be assessed using the Gastroesophageal Reflux Disease Questionnaire (GerdQ). The total GerdQ score ranges from 0 to 18, with higher scores indicating more severe GERD symptoms. Complete symptom resolution will be defined as a score of 0 for both the heartburn and regurgitation items of the GerdQ. The proportion of participants achieving complete symptom resolution at 4 weeks will be compared between the two study groups.

    Time frame: 4 weeks

  3. Change in Traditional Medicine Symptoms of Liver-Stomach Heat Stagnation Syndrome

    Traditional medicine symptoms of Liver-Stomach Stagnated Heat syndrome will be assessed using a syndrome symptom score comprising two main symptoms (burning sensation and acid regurgitation) and six secondary symptoms (retrosternal pain, epigastric burning pain, epigastric fullness, belching or food regurgitation, irritability, and rapid hunger). Each main symptom is rated as absent, mild, moderate, or severe and scored 0, 2, 4, or 6 points, respectively. Each secondary symptom is rated as absent, mild, moderate, or severe and scored 0, 1, 2, or 3 points, respectively. The total score ranges from 0 to 30, with higher scores indicating greater syndrome severity. Change in the total syndrome score from baseline through 4 weeks will be compared between the two study groups.

    Time frame: Baseline and weekly through 4 weeks

  4. Treatment Response Based on Liver-Stomach Stagnated Heat Syndrome Score

    Treatment response for Liver-Stomach Stagnated Heat syndrome will be assessed using the percentage reduction in the total syndrome score from baseline. The efficacy index will be calculated as \[(baseline score - post-treatment score) / baseline score\] × 100. Clinical cure is defined as an efficacy index of at least 95%, markedly effective as 70% to less than 95%, effective as 30% to less than 70%, and ineffective as less than 30%. The proportion of participants classified as clinically cured, markedly effective, effective, or ineffective at 4 weeks will be compared between the two study groups.

    Time frame: Baseline and 4 weeks

  5. Adverse Events Associated With Thread-Embedding Acupuncture

    Adverse events associated with thread-embedding acupuncture will be monitored throughout the 4-week treatment period. Events of interest include local pain, bleeding, bruising, swelling, infection, allergic reactions, and other treatment-related complications. The number and proportion of participants experiencing at least one adverse event will be recorded and compared between the two study groups.

    Time frame: Throughout the 4-week treatment period

07

Study locations

1 of 1 sites recruiting
  • Traditional Medicine Hospital of Ho Chi Minh City
    Ho Chi Minh City, Vietnam
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07797959
Lead sponsor
University of Science Ho Chi Minh City
Responsible party
Dr Nguyen Ngo Le Minh Anh MD, PhD (Principal Investigator, University of Medicine and Pharmacy at Ho Chi Minh City) — Principal investigator
First posted
Sep 1, 2026
Start date
Apr 15, 2026
Primary completion
Sep 15, 2026 (estimated)
Completion
Sep 18, 2026 (estimated)
Last update
Sep 1, 2026

Study contacts

Minh-Anh Nguyen Ngo Le, MD, PhD
Contact
drminhanh@ump.edu.vn
+84 962 644 648
Minh-Anh Nguyen Ngo Le, MD,PhD
principal investigator · University of Medicine and Pharmacy at Ho Chi Minh City
Minh-Anh Nguyen Ngo Le, MD, PhD
principal investigator · University of Medicine and Pharmacy at Ho Chi Minh City

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion